Animation Review: The Human Pangenome
Appeared in BioNews 1085
When the Human Genome Project was completed in 2000, Bill Clinton, then president of the United States, called it the most important, most wondrous map ever produced by humankind . This seemed undisputable at the time, for the completion of this research was a true triumph of science and technology and seemed poised to help scientists uncover countless secrets about our species.
To a certain extent this goal has been achieved, as an increased understanding of human sequence variation has allowed the roots of genetic diseases to be investigated, and the technology developed in the original project has allowed for the completion of further landmark projects that have enhanced the practice of medicine, such as The Cancer Genome Atlas. But is this only a glimmer of the true potential of a reference genome?
EGFR Resisters and LUNGevity Foundation Partner on Lung Cancer Research Award prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
IU researchers identify how breast cancer cells evade immune attacks
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have identified how breast cancer cells hide from immune cells to stay alive. The discovery could lead to better immunotherapy treatment for patients.
Xinna Zhang, PhD, and colleagues found that when breast cancer cells have an increased level of a protein called MAL2 on the cell surface, the cancer cells can evade immune attacks and continue to grow. The findings are published this month in
The Journal of Clinical Investigation and featured on the journal s cover.
The lead author of the study, Zhang is a member of the IU Simon Comprehensive Cancer Center and assistant professor of medical and molecular genetics at IU School of Medicine.
E-Mail
WASHINGTON, DC - Investigators leading the Lung Cancer Master Protocol, or Lung-MAP trial, will present findings from three translational medicine studies at the 2020 World Conference on Lung Cancer, to be held online January 28-31, 2021.
The presentations will mark the first time that investigators share translational medicine insights from Lung-MAP, the first large-scale precision medicine trial in lung cancer backed by the National Cancer Institute (NCI), part of the National Institutes of Health, and the first major NCI trial to test multiple treatments, simultaneously, under one umbrella design. Since it launched in June 2014, the trial has tested 12 new lung cancer drugs. Lung-MAP has also amassed a scientifically valuable cache of data and biospecimens from 3,021 patients.
E-Mail
INDIANAPOLIS Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have identified how breast cancer cells hide from immune cells to stay alive. The discovery could lead to better immunotherapy treatment for patients.
Xinna Zhang, PhD, and colleagues found that when breast cancer cells have an increased level of a protein called MAL2 on the cell surface, the cancer cells can evade immune attacks and continue to grow. The findings are published this month in
The Journal of Clinical Investigation and featured on the journal s cover.
The lead author of the study, Zhang is a member of the IU Simon Comprehensive Cancer Center and assistant professor of medical and molecular genetics at IU School of Medicine.